A5068846586- Antiplatelet Therapy and Cardiovascular Diseases
- Atrial Fibrillation Management and Outcomes
- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Venous Thromboembolism Diagnosis and Management
- Lipoproteins and Cardiovascular Health
- Cardiac electrophysiology and arrhythmias
- Analytical Methods in Pharmaceuticals
- Cardiac Arrhythmias and Treatments
- Heart Failure Treatment and Management
- Pharmacogenetics and Drug Metabolism
- Cardiac Imaging and Diagnostics
- Platelet Disorders and Treatments
- Vitamin K Research Studies
- Antibiotics Pharmacokinetics and Efficacy
- Cardiac Valve Diseases and Treatments
- Pharmaceutical studies and practices
- Cardiac pacing and defibrillation studies
- Blood Pressure and Hypertension Studies
- Poisoning and overdose treatments
- Inflammatory mediators and NSAID effects
- Peripheral Artery Disease Management
- Cardiovascular Function and Risk Factors
- Pharmacological Effects and Toxicity Studies
- Synthesis of β-Lactam Compounds
Universitäts-Herzzentrum Freiburg-Bad Krozingen
2015-2024
University of Freiburg
2010-2024
University Medical Center Freiburg
2022-2023
University of Pecs
2020
Semmelweis University
2020
Balaton Limnological Institute
2020
University of Bern
2019
LMU Klinikum
2018
Ludwig-Maximilians-Universität München
2018
Klinikum Ludwigshafen
2015
Background— The increasing use of higher-than-approved doses clopidogrel in clinical practice is based part on the desire for greater levels inhibition platelet aggregation (IPA). Prasugrel a new thienopyridine that more potent than standard-dose healthy subjects and patients with stable coronary artery disease. relative antiplatelet effects prasugrel versus high-dose percutaneous intervention are unknown. Methods Results— Comparison to Clopidogrel Inhibition Platelet Activation...
The relative merits of ticagrelor as compared with prasugrel in patients acute coronary syndromes for whom invasive evaluation is planned are uncertain.In this multicenter, randomized, open-label trial, we randomly assigned who presented and was to receive either or prasugrel. primary end point the composite death, myocardial infarction, stroke at 1 year. A major secondary (the safety point) bleeding.A total 4018 underwent randomization. end-point event occurred 184 2012 (9.3%) group 137...
Background— Pretreatment with clopidogrel can reduce the risks associated percutaneous coronary intervention (PCI). To shorten time for to become effective, a 600-mg loading dose has been used. We sought validate this regimen in large cohort and investigated dependence of antiplatelet effect 600 mg clopidogrel. Methods Results— Our study included 1001 patients who were scheduled cardiac catheterization as potential candidates PCI. obtained blood samples before administration at...
Optimizing outcomes after percutaneous coronary intervention (PCI) requires balancing between the risks of thrombotic and bleeding events in individual patients. 1 -3 However, finding optimal balance is not always straightforward since complications may differ extremely individuals.In addition, effects anticoagulant antiplatelet drugs are uniform 4ecent European guidelines 1,3 recommend use prasugrel or ticagrelor instead clopidogrel all PCI-treated acute syndrome (ACS) patients without...
BackgroundStent thrombosis (ST) is a rare but serious complication following percutaneous coronary intervention. Analysis of thrombus composition from patients undergoing catheter thrombectomy may provide important insights into the pathological processes leading to formation. We performed large-scale multicentre study evaluate specimens in with ST across Europe.
Left atrial (LA) low-voltage substrate (LVS) potentially slows intra-atrial conduction, which might identify patients at risk for arrhythmia recurrence following pulmonary vein isolation (PVI).Up to 50% of with persistent fibrillation (AF) have PVI, mostly due arrhythmogenic LA LVS.Seventy-two AF underwent electrocardioversion sinus rhythm and high-density voltage mapping the left atrium. Invasively measured activation time P-wave duration (PWD; total PWD [measured from -dV/dt in leads V1 V2...
Medication non-adherence is frequent and associated with high morbidity mortality in patients chronic heart failure (CHF). We investigated whether an interdisciplinary intervention improves adherence elderly CHF patients.The study population (mean age 74 years, 62% male, mean left ventricular ejection fraction 47%, 52% New York Heart Association class III) consisted of 110 randomized into the pharmacy care 127 usual group. The median follow-up was 2.0 years (interquartile range 1.2-2.7)....
Abstract Aims Clopidogrel is prescribed for the prevention of atherothrombotic events. While investigations have identified genetic determinants inter-individual variability in on-treatment platelet inhibition (e.g. CYP2C19*2), evidence that these variants clinical utility to predict major adverse cardiovascular events (CVEs) remains controversial. Methods and results We assessed impact 31 candidate gene polymorphisms on adenosine diphosphate (ADP)-stimulated reactivity 3391...
The mechanism of cephalosporin‐induced hypoprothrombinemia has been investigated in hospitalized patients, with respect to cephalosporin structure, vitamin K metabolism, and status. Cephalosporins containing side chains N‐methylthiotetrazole (latamoxef, cefmenoxime, cefoperazone, cefotetan, cefamandole) or methyl‐thiadiazole (cefazolin) all caused the transient plasma appearance 1 2,3‐epoxide response a 10‐mg intravenous dose , whereas two cephalosporins without heterocyclic chain...
To investigate the incidence of postoperative generalized seizures in patients undergoing aortic valve replacement (AVR) under extracorporeal circulation, who received either high-dose tranexamic acid (TXA) or epsilon aminocaproic (EACA) as an antifibrinolytic agent.This retrospective analysis comprised 682 consecutive AVR with without simultaneous coronary artery bypass surgery. Patients operated on before March 2008 were treated intra-operatively TXA (100 mg kg⁻¹; n = 341), after EACA (50...
Background— Recently published data indicate that the paraoxonase-1 ( PON1 ) Q192R genotype—and not as previously shown activity of cytochrome P450 (CYP) 2C19—is major determinant metabolic bioactivation clopidogrel and thereby variability antiplatelet effect clopidogrel. We sought to investigate whether gene polymorphism affects platelet reactivity in patients undergoing elective coronary stent placement. Methods Results— The study included 760 consecutive placement after loading with 600...